Company
PureTech Health
LON:PRTC
PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others.
44 stories · page 1 of 3
PureTech Health and Nektar Therapeutics end tie-up talks
PureTech shares dropped 4.8% to 217.50p in midmorning trade
PureTech Health confirms ‘possible combination’ with Nektar Therapeutics
“PureTech and Nektar remain in discussions regarding the proposal," the clinical-stage biotherapeutics company said
PureTech Health provides the blue-print for value creation in the life sciences sector
The company has hit two home runs and has a fat-to-bursting drug pipeline. The rigorous approach of the PureTech team, led by founder Daphne Zohar, helps explain its success, which some supporters argue has yet to be fully recognised by the
PureTech Health extends cash runway by one year to 2025
“PureTech announced that its cash runway now extends out to Q1 25, an advance of a full year over the previous guidance,” Peel Hunt noted
PureTech Health gets US clearance for ADHD prescription to be delivered through video game
Half of parents saw a clinically meaningful change in their child's day-to-day impairments after one month of usage, increasing to 68% after two months
Archive
FTSE 100 closes 2.9% higher as US Fed unveils US$2.3 trillion lending facility; jobless claims soar
Britain's blue-chip benchmark finished nearly 165 points higher, or 2.9% at 5,842
Thursday’s Horror show economic stats set to dominate agenda
The next round of economic stats aren't expected to make positive reading.
PureTech affiliate Gelesis secures $85mln to launch obesity drug in US
Of these, US$63.4mln were raised by equity funding alongside a US$12.9mln grant by the European Regional Development Fund plus a US$8.3mln long-term loan
PureTech loses ground after Karuna investment raises new funds
The Nasdaq-listed biopharma company put 2mln shares of its common stock on sale to the public at US$96 each
PureTech Health surges as Karuna investment rockets 442%
The Nasdaq-listed company soared after announcing that its lead asset KarXT reported an above-average result in phase II of trials on schizophrenic patients
PureTech shares jump as Gelesis approval caps “transformational” six months
PureTech owns a 20% stake in Gelesis, whose Plenity weight reduction aid was given the green light by US regulators earlier this year
Archive
FTSE 100 set for stumbling start after Wall Street rebound
The FTSE is being called around seven points lower on Tuesday
Archive
FTSE 100 closes in the red as resource stocks come off the boil
After hitting a six-month high on Tuesday afternoon, London's blue-chips took a step back on Wednesday
Archive
Primark owner AB Foods to take results spotlight on Wednesday
Primark’s performance is an all-important indicator for the FTSE 100 firm, especially with its sugar division continuing to struggle amid falling prices in the EU